Esperion appoints Benjamin O. Looker as General Counsel effective Jan 1, 2022

Esperion Therapeutics, Inc.

Appointed Benjamin O. Looker as General Counsel effective Jan 1, 2022, reporting to CEO Sheldon Koenig.
Looker previously served as GC of Trillium Therapeutics until its acquisition by Pfizer in Nov 2021.
Compensation includes $375k base salary, 40% target bonus, option for 100,450 shares, and 70,800 RSUs.
Looker will lead legal, compliance, and ethics operations, with focus on upcoming CLEAR Outcomes trial results.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Benjamin O. Looker

General Counsel

ESPR · Esperion Therapeutics, Inc.

Effective: 2022-01-01
Filed: January 4, 2022, 6:59 PM ET

On January 4, 2022, Esperion Therapeutics, Inc. (the “Company”) announced the appointment of Benjamin O. Looker as the Company’s General Counsel pursuant to the terms of an employment agreement with Mr. Looker (the “Looker Agreement”), effective as of January 1, 2022 (the “Start Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Benjamin O. Looker was appointed as General Counsel at Esperion Therapeutics, Inc..

Action: appointed
Role: General Counsel

Exact text from the filing

On January 4, 2022, Esperion Therapeutics, Inc. (the “Company”) announced the appointment of Benjamin O. Looker as the Company’s General Counsel pursuant to the terms of an employment agreement with Mr. Looker (the “Looker Agreement”), effective as of January 1, 2022 (the “Start Date”).

View on SEC.gov

Esperion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-000142

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.